Similarly, there have been reports of patients receiving a combination of PD-L1 monoclonal antibody atezolizumab with etoposide and carboplatin for advanced small cell lung cancer, presenting with symptoms of abdominal distension, diarrhea, and constipation, ultimately leading to consideration of immune therapy-related intestinal obstruction (8). This evidence concerns the gene CD274 and intestinal obstruction.